RESMETIROM
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.7M | 13,832 | 7,511 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 144 | 75.5% |
| Food and Beverage | $370,657 | 13,659 | 21.9% |
| Honoraria | $43,445 | 24 | 2.6% |
| Travel and Lodging | $1,651 | 5 | 0.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | Madrigal Pharmaceuticals | $1.3M | 0 |
Top Doctors Receiving Payments for RESMETIROM — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Internal Medicine | Los Angeles, CA | $493.88 | 15 |
| , MD | Transplant Surgery | Los Angeles, CA | $486.71 | 5 |
| , M.D | Transplant Hepatology | Los Angeles, CA | $486.14 | 4 |
| , PA | Physician Assistant | Chandler, AZ | $478.43 | 9 |
| , PA-C | Physician Assistant | New York, NY | $443.80 | 12 |
| , MD | Gastroenterology | New York, NY | $430.39 | 5 |
| , MD., MPH | Gastroenterology | Weston, FL | $416.50 | 11 |
| , M.D | Family Medicine | Lynwood, CA | $413.99 | 11 |
| , M.D | Gastroenterology | Lake Success, NY | $408.45 | 8 |
| , M.D | Gastroenterology | Honolulu, HI | $408.05 | 5 |
| Lavinia Goldstein | Physician Assistant | Miami, FL | $398.71 | 5 |
| , MD | Gastroenterology | Wynnewood, PA | $393.99 | 12 |
| , M.D | Gastroenterology | Metuchen, NJ | $391.12 | 26 |
| , D.O | Internal Medicine | Mobile, AL | $386.95 | 9 |
| , PA | Physician Assistant | Miami, FL | $385.62 | 5 |
| , M.D | Surgery | New Orleans, LA | $382.91 | 3 |
| , FNP | Family | Richmond, VA | $379.45 | 7 |
| , M.D | Gastroenterology | Los Angeles, CA | $374.95 | 3 |
| , RN, MSN, ANP, MPH | Adult Health | Los Angeles, CA | $373.05 | 3 |
| , NP | Adult Health | Salem, VA | $372.13 | 6 |
| , M.D | Hepatology | Pasadena, CA | $369.94 | 4 |
| , MD | Gastroenterology | Providence, RI | $369.74 | 6 |
| , ACNP-BC | Acute Care | Shreveport, LA | $366.68 | 6 |
| , MD | Transplant Hepatology | Atlanta, GA | $365.36 | 7 |
| , FNP | Nurse Practitioner | Glendale, AZ | $356.12 | 5 |
Manufacturing Companies
- Madrigal Pharmaceuticals $1.7M
Product Information
- Type Drug
- Total Payments $1.7M
- Total Doctors 7,511
- Transactions 13,832
About RESMETIROM
RESMETIROM is a drug associated with $1.7M in payments to 7,511 healthcare providers, recorded across 13,832 transactions in the CMS Open Payments database. The primary manufacturer is Madrigal Pharmaceuticals.
Payment data is available from 2024 to 2024. In 2024, $1.7M was paid across 13,832 transactions to 7,511 doctors.
The most common payment nature for RESMETIROM is "Unspecified" ($1.3M, 75.5% of total).
RESMETIROM is associated with 1 research study, including "A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)" ($1.3M).